Hepatotoxicity Study of Voriconazole Therapy in Patients with Invasive Fungal Infections / 中国药学杂志

ABSTRACT

OBJECTIVE: To explore the factors that association with voriconazole-related hepatotoxicity in patients with invasive fungal infections. METHODS: Voriconazole trough plasma concentrations(ρmin) were measured by high-performance liquid chromatography(HPLC). Voriconazole-related hepatotoxicity was defined according to Common Terminology Criteria for Adverse Events(CTCAE), and the multivariate linear regression and classification and regression tree(CART) were used to explore the factors that association with hepatotoxicity. RESULTS: A total of 328 samples from 144 patients were measured, and 18 patients with signs of hepatotoxicity. There was a significant difference between the voriconazole ρmin in patients with hepatotoxicity and those without hepatotoxicity [(3.49 ± 2.31) μg•mL-1 vs (1.96 ± 1.48 ) μg•mL-1, P 2.89 μg•mL-1; ③non-poor metabolizer with voriconazole ρmin > 2.89 μg•mL-1 who received CYP2C19 inhibitor. CONCLUSION: Monitoring voriconazole ρmin and liver function could benefit to the safety of voriconazole therapy in patients with invasive fungal infections.